*From the authors*

We thank Drs. Garbers and Rose-John for their interest in our study, where we found that a loss-of-function polymorphism in the interleukin-6 receptor (*IL6R*) gene reduces risk of the *JAK2*V617F somatic mutation and myeloproliferative neoplasm [@bib0001]. They raise some interesting points related to the underlying mechanism of soluble IL6R (sIL6R) and its relationship with tocilizumab treatment, a monoclonal antibody that targets the IL6R [@bib0002].

We used the genetic polymorphism rs4537545 that is in high linkage disequilibrium with rs2228145 in the *IL6R* gene, which causes the non-synonymous exchange of Asp-358 to Ala-358 in the IL6R protein. This results in reduced membrane-bound IL6R due to increased proteolytic cleavage followed by increased sIL6R concentration \[[@bib0001],[@bib0003]\]. This blocks the classical signalling pathway of IL6R and thereby dampens inflammation. Indeed, as emphasized by Garbers and Rose-John, increased sIL6R in combination with soluble glycoprotein-130 in the blood circulation can act as a natural buffer that can neutralize IL6, thereby also dampen inflammation \[[@bib0001],[@bib0004],[@bib0005]\].

We agree that tocilizumab treatment, with reservations to its pharmacokinetic properties, will potentially block all sIL6R molecules thereby rendering them biologically inactive. In contrast, sIL6R molecules in individuals with genetic polymorphism in *IL6R* are fully biologically active. Although the two scenarios may not be fully comparable, it does not change the notion that treatment with tocilizumab and other agents that target the same inflammatory pathway such as canakinumab, a monoclonal antibody that targets the more central regulator interleukin-1β, could potentially be considered as candidate drugs for myeloproliferative neoplasms.
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